跳至主要内容
临床试验/IRCT20190810044500N5
IRCT20190810044500N5已完成3 期

Investigation of the efficacy and safety of colchicine In combination with standard treatment on covid-19 patients: A clinical trial

Yazd University of Medical Sciences0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
All

入选标准

  • Age 18 to 70 years
  • - Detection of COVID-19 in the last 24 to 48 hours
  • - Candidate for hospitalization (o2sat <93% or RR> 24 or Pao2 / Fio2 <300)
  • - COVID-19 patients hospitalized with hospital indications according to the guideline of the country that has pulmonary infiltration in CT scan
  • -Not being pregnant and not becoming pregnant until 30 days after the end of the study
  • - No consumption of colchicine during the last week ( due to the half-life of 20-40 hours of the drug)
  • - Outpatients with pulmonary infiltration on CT scan

排除标准

  • Patients with a history of Crohn or Ulcerative colitis, diarrhea, or chronic malabsorption
  • Neuromuscular diseases
  • GFR less than 30 ml per minute
  • History of cirrhosis, hepatitis and severe liver disease
  • Patients receiving chemotherapy for cancer
  • Patients currently taking colchicine for other uses, such as gout or Mediterranean fever
  • Patients with a history of allergic reactions or allergies to colchicine
  • Pregnancy and lactation

研究者

发起方
Yazd University of Medical Sciences

相似试验